menu search

PSTV / Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago. Read More
Posted: Apr 20 2023, 19:01
Author Name: Zacks Investment Research
Views: 112375

PSTV News  

Plus Therapeutics, Inc. (PSTV) Q3 2023 Earnings Call Transcript

By Seeking Alpha
October 31, 2023

Plus Therapeutics, Inc. (PSTV) Q3 2023 Earnings Call Transcript

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President an more_horizontal

Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference

By GlobeNewsWire
September 11, 2023

Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical compa more_horizontal

Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 14, 2023

Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Call Transcript

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q2 2023 Earnings Conference Call August 14, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and more_horizontal

Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023

By GlobeNewsWire
August 8, 2023

Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company more_horizontal

Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

By GlobeNewsWire
August 3, 2023

Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company more_horizontal

Plus Therapeutics to Present at the 2023 Virtual June Investor Summit

By GlobeNewsWire
May 25, 2023

Plus Therapeutics to Present at the 2023 Virtual June Investor Summit

AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company more_horizontal

Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript

By Seeking Alpha
April 20, 2023

Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript

Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript. more_horizontal

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
April 20, 2023

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 p more_horizontal


Search within

Pages Search Results: